27 completed, 3 terminated, 2 unknown, 1 recruiting. 11 Phase 3, 9 Phase 2, 5 Phase 1, 4 Not applicable, 3 Phase 4.
Follow Sevelamer carbonate: new trials by email Literature Review of Sevelamer carbonate trials Research Report on Sevelamer carbonate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia | Phase 2 | Recruiting | Jemincare | 50 | 2024-12-30 | 2025-02-03 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat Vadadustat, Sevelamer carbonate, Calcium acetate - Healthy Volunteers | Phase 1 | Completed | Akebia Therapeutics | 54 | 2020-06-15 | 2020-10-08 |
| Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines calcium carbonate, sevelamer carbonate - Chronic Kidney Diseases | Not applicable | Unknown | University College, London | 21 | 2020-01-07 | 2021-08-12 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric Citrate, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Panion & BF Biotech Inc. | 240 | 2019-06-19 | 2021-03-10 |
| A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Tenapanor, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 4 | Completed | Ardelyx | 172 | 2019-06-15 | 2023-03-29 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4 Sevelamer Carbonate - CKD Stage 3b, CKD Stage 4 | Phase 3 | Unknown | Fan Fan Hou | 80 | 2018-09-01 | 2018-08-07 |
| PA21 Safety and Efficacy in Adult Chinese Subjects PA21, sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 286 | 2018-08-31 | 2021-06-02 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Tenapanor, Placebo, Sevelamer Carbonate - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 1559 | 2018-01-08 | 2023-06-29 |
| DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis DS-2330b PIB, Placebo, Sevelamer - Hyperphosphatemia | Phase 1 | Completed | Daiichi Sankyo | 40 | 2017-08-17 | 2019-03-25 |
| A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis EOS789, Placebo, Renvela - Hyperphosphatemia | Phase 1 | Completed | Chugai Pharmaceutical | 26 | 2016-12-01 | 2018-09-13 |
| A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 AZD1722, Renvela - Healthy | Phase 1 | Completed | Ardelyx | 16 | 2013-04-01 | 2015-01-27 |
| An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease Placebo, Sevelamer carbonate - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Genzyme, a Sanofi Company | 101 | 2012-05-01 | 2016-07-25 |
| The Effects of Sevelamer Carbonate on Diabetic Nephropathy Sevelamer Carbonate, calcium carbonate - Diabetic Nephropathy | Phase 2 | Completed | Gary Striker | 117 | 2012-02-01 | 2014-04-09 |
| Sevelamer for Reducing Endotoxemia and Immune Activation Sevelamer carbonate - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 40 | 2011-11-01 | 2018-10-11 |
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care: - Adenovirus, Anesthesia | Completed | Daniel Benjamin | 3520 | 2011-11-01 | 2023-09-06 | |
| Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Calcium acetate oral solution (COS), Sevelamer carbonate - Chronic Kidney Disease | Phase 4 | Completed | Fresenius Medical Care North America | 38 | 2011-09-01 | 2016-01-14 |
| A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis | Phase 3 | Completed | Vifor Pharma | 659 | 2011-09-01 | 2014-04-01 |
Showing 20 of 33. Sign in to see all of them.
Hyperphosphatemia (14) · Renal Insufficiency, Chronic (14) · Kidney Failure, Chronic (5) · Hyperparathyroidism, Secondary (3) · Cardiovascular Diseases (2) · Diabetic Nephropathies (2) · Inflammation (2) · Vascular Calcification (2) · Adenoviridae Infections (1) · Anxiety Disorders (1) · Arrhythmias, Cardiac (1) · Atherosclerosis (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Bradycardia (1)
Ardelyx (4) · Genzyme, a Sanofi Company (4) · Vifor Pharma (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Akebia Therapeutics (1) · Albany College of Pharmacy and Health Sciences (1) · Alebund Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Centre Hospitalier Universitaire, Amiens (1) · Chugai Pharmaceutical (1) · Daiichi Sankyo (1) · Daniel Benjamin (1) · Denver Nephrologists, P.C. (1) · Fan Fan Hou (1) · Fresenius Medical Care North America (1)
United States (21) · China (7) · United Kingdom (5) · Germany (4) · Austria (3) · France (3) · Lithuania (3) · Poland (3) · Belgium (2) · Canada (2) · Croatia (2) · Czechia (2) · Latvia (2) · Romania (2) · Russia (2)
David P Rosenbaum, PhD (3) · Juergen Floege, MD (2) · Charles J Ferro, BSc (Hons), MBChB, FRCP, MD (1) · Chi Hornik, PharmD (1) · Darius L Mason, Pharm.D. (1) · David P Rosenbaum, Ph.D. (1) · Fan Fan Hou, M.D.,PhD (1) · Gabriel Choukroun, Ph D, M D (1) · Gary Striker, MD (1) · Geoffrey A Block, MD (1) · Helen Vlassara, MD (1) · Hou Fanfan, MD (1)
PMID 40576086, PMID 38323855, PMID 29656600, PMID 37853560, PMID 21288351, PMID 22461535, PMID 24614374, PMID 24864123, PMID 24949994, PMID 25685872, PMID 26039810, PMID 26926644, PMID 26951967, PMID 27357090, PMID 27522443, PMID 28137820, PMID 28290120, PMID 28779462, PMID 29074818, PMID 29084742, PMID 29271816, PMID 29435949, PMID 29677389, PMID 29779023, PMID 30790601, PMID 31317556, PMID 31548185, PMID 31814149, PMID 32324313, PMID 32497307, PMID 33029806, PMID 33766811, PMID 33903114, PMID 34302290, PMID 34599865, PMID 35370711, PMID 35372979, PMID 35491971, PMID 37473746, PMID 38453435, PMID 41247430
2008 (1), U01AI068636 (1)